Vaxcyte files separate $500M offerings for equity/pre-funded warrants and 2032 convertible notes

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants ...

SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of…

Vaxcyte files separate $500M offerings for equity/pre-funded warrants and 2032 convertible notes

Latham Advises on Vaxcyte’s Concurrent Public Offerings of Common Stock, Pre-Funded Warrants, and Convertible Senior Notes

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, has announced the pricing of concurrent underwritten...

Vaxcyte prices US$1B stock, warrants and notes

Vaxcyte expects both underwritten offerings to close Oct. 9, adding funds for adult vaccine trials and manufacturing ahead of a planned U.S. filing.

About $500 million is expected from stock and $500 million from bonds. Vaxcyte plans to fund vaccine work.

Vaxcyte intends to use net proceeds for VAX-31 trials, manufacturing scale-up and U.S. launch preparation; offerings are expected to close Oct. 9.